The heart is one of the first organ to form during development of the body. Each year cardiovascular diseases (CVD) are the most common cause of the deaths in Europe and the world. Statistics on cardiovascular diseases show that they are the leading cause of death in the EU, resulting mainly in heart attacks and strokes. The heart cells can’t heal itself unlike the other organ parts of the body. Cardiomyocytes face challenges to use for many novel applications but the research implementation on cardiomyocytes is limited.

Human cardiomyocytes derived from iPS cells are ideal to fulfill their potential in cardiotoxicity testing, high-throughput drug screening, metabolism analysis and electrophysiology as well as model of the human modeling of cardiac diseases.

We provide cutting-edge cardiotoxicity assessments using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Our advanced 2D monolayer and 3D spheroid cardiac models, combined with automated imaging and analysis, enable accurate, early detection of compound-induced cardiac effects. By identifying potential liabilities long before clinical trials, we help our partners reduce development risks, save time and costs, and bring safer drugs to patients faster.

We provide cutting-edge cardiotoxicity assessments using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Our advanced 2D monolayer and 3D spheroid cardiac models, combined with automated imaging and analysis, enable accurate, early detection of compound-induced cardiac effects. By identifying potential liabilities long before clinical trials, we help our partners reduce development risks, save time and costs, and bring safer drugs to patients faster.